Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 May;73(10):1272–1277. doi: 10.1038/bjc.1996.244

High-dose chemotherapy and autologous bone marrow transplant in relapsed Hodgkin's disease--a pragmatic prognostic index.

M E O'Brien 1, S Milan 1, D Cunningham 1, A L Jones 1, M Nicolson 1, P Selby 1, T Hickish 1, M Hill 1, M E Gore 1, C Viner 1
PMCID: PMC2074518  PMID: 8630292

Abstract

High-dose chemotherapy with autologous bone marrow transplantation is used in the treatment of relapsed or high-risk Hodgkin's disease. As prospective randomised studies have proved difficult to accrue to, current recommendations are based on the reports of large series of prospectively collected data. We have looked at the outcome of 89 patients treated in this way at a single institution and have developed an index to predict outcome. Of 89 patients, with a median age of 29 years (range 15-51 years), eight patients were in first complete remission/partial remission (CR/PR), 17 in second or later CR, 37 were responding relapses, 13 resistant relapses, 11 primary refractory and three untested relapses. Combinations of melphalan, BCNU and etoposide were given in all cases except in ten patients who received melphalan alone. The median follow-up was 43 months (range 6-77 months). A total of 24 patients were in CR at the time of autologous bone marrow transplantation (ABMT), 33 achieved CR with ABMT, 16 PR, to give a response rate to ABMT of 49/65 = 74% (95% CI 60-83%) with a CR rate of 51% (CI 36-62%). In a Cox's multivariate analysis the most important factors in predicting outcome after ABMT were response to treatment before entry, number of previous treatments and previous chemosensitivity. Using these factors we devised a prognostic index which reliably selects a group of patients (65%) with at least a 70% chance of being progression free from 1 year onwards. Patients who have never achieved a CR and have received three or more chemotherapy regimens do not benefit from high-dose chemotherapy as used in this study.

Full text

PDF
1272

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson J. E., Litzow M. R., Appelbaum F. R., Schoch G., Fisher L. D., Buckner C. D., Petersen F. B., Crawford S. W., Press O. W., Sanders J. E. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience. J Clin Oncol. 1993 Dec;11(12):2342–2350. doi: 10.1200/JCO.1993.11.12.2342. [DOI] [PubMed] [Google Scholar]
  2. Bierman P. J., Bagin R. G., Jagannath S., Vose J. M., Spitzer G., Kessinger A., Dicke K. A., Armitage J. O. High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients. Ann Oncol. 1993 Nov;4(9):767–773. doi: 10.1093/oxfordjournals.annonc.a058662. [DOI] [PubMed] [Google Scholar]
  3. Carella A. M., Congiu A. M., Gaozza E., Mazza P., Ricci P., Visani G., Meloni G., Cimino G., Mangoni L., Coser P. High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an Italian study group report. J Clin Oncol. 1988 Sep;6(9):1411–1416. doi: 10.1200/JCO.1988.6.9.1411. [DOI] [PubMed] [Google Scholar]
  4. Chopra R., McMillan A. K., Linch D. C., Yuklea S., Taghipour G., Pearce R., Patterson K. G., Goldstone A. H. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood. 1993 Mar 1;81(5):1137–1145. [PubMed] [Google Scholar]
  5. Crump M., Smith A. M., Brandwein J., Couture F., Sherret H., Sutton D. M., Scott J. G., McCrae J., Murray C., Pantalony D. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant. J Clin Oncol. 1993 Apr;11(4):704–711. doi: 10.1200/JCO.1993.11.4.704. [DOI] [PubMed] [Google Scholar]
  6. Gianni A. M., Siena S., Bregni M., Lombardi F., Gandola L., Di Nicola M., Magni M., Peccatori F., Valagussa P., Bonadonna G. High-dose sequential chemo-radiotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin's disease--a 6-year update. Ann Oncol. 1993 Dec;4(10):889–891. doi: 10.1093/oxfordjournals.annonc.a058399. [DOI] [PubMed] [Google Scholar]
  7. Harding M., Selby P., Gore M., Perren T., Treleavan J., Mansi J., Zulian G., Milan S., Meldrum M., Viner C. High-dose chemotherapy and autologous bone marrow transplantation for relapsed and refractory Hodgkin's disease. Eur J Cancer. 1992;28A(8-9):1396–1400. doi: 10.1016/0959-8049(92)90528-a. [DOI] [PubMed] [Google Scholar]
  8. Jagannath S., Armitage J. O., Dicke K. A., Tucker S. L., Velasquez W. S., Smith K., Vaughan W. P., Kessinger A., Horwitz L. J., Hagemeister F. B. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol. 1989 Feb;7(2):179–185. doi: 10.1200/JCO.1989.7.2.179. [DOI] [PubMed] [Google Scholar]
  9. Jones R. J., Piantadosi S., Mann R. B., Ambinder R. F., Seifter E. J., Vriesendorp H. M., Abeloff M. D., Burns W. H., May W. S., Rowley S. D. High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol. 1990 Mar;8(3):527–537. doi: 10.1200/JCO.1990.8.3.527. [DOI] [PubMed] [Google Scholar]
  10. Linch D. C., Winfield D., Goldstone A. H., Moir D., Hancock B., McMillan A., Chopra R., Milligan D., Hudson G. V. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet. 1993 Apr 24;341(8852):1051–1054. doi: 10.1016/0140-6736(93)92411-l. [DOI] [PubMed] [Google Scholar]
  11. Lohri A., Barnett M., Fairey R. N., O'Reilly S. E., Phillips G. L., Reece D., Voss N., Connors J. M. Outcome of treatment of first relapse of Hodgkin's disease after primary chemotherapy: identification of risk factors from the British Columbia experience 1970 to 1988. Blood. 1991 May 15;77(10):2292–2298. [PubMed] [Google Scholar]
  12. Longo D. L., Duffey P. L., Young R. C., Hubbard S. M., Ihde D. C., Glatstein E., Phares J. C., Jaffe E. S., Urba W. J., DeVita V. T., Jr Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol. 1992 Feb;10(2):210–218. doi: 10.1200/JCO.1992.10.2.210. [DOI] [PubMed] [Google Scholar]
  13. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  14. Philip T., Armitage J. O., Spitzer G., Chauvin F., Jagannath S., Cahn J. Y., Colombat P., Goldstone A. H., Gorin N. C., Flesh M. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med. 1987 Jun 11;316(24):1493–1498. doi: 10.1056/NEJM198706113162401. [DOI] [PubMed] [Google Scholar]
  15. Phillips G. L., Wolff S. N., Herzig R. H., Lazarus H. M., Fay J. W., Lin H. S., Shina D. C., Glasgow G. P., Griffith R. C., Lamb C. W. Treatment of progressive Hodgkin's disease with intensive chemoradiotherapy and autologous bone marrow transplantation. Blood. 1989 Jun;73(8):2086–2092. [PubMed] [Google Scholar]
  16. Rapoport A. P., Rowe J. M., Kouides P. A., Duerst R. A., Abboud C. N., Liesveld J. L., Packman C. H., Eberly S., Sherman M., Tanner M. A. One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretransplant disease status for predicting outcome. J Clin Oncol. 1993 Dec;11(12):2351–2361. doi: 10.1200/JCO.1993.11.12.2351. [DOI] [PubMed] [Google Scholar]
  17. Reece D. E., Barnett M. J., Connors J. M., Fairey R. N., Fay J. W., Greer J. P., Herzig G. P., Herzig R. H., Klingemann H. G., LeMaistre C. F. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol. 1991 Oct;9(10):1871–1879. doi: 10.1200/JCO.1991.9.10.1871. [DOI] [PubMed] [Google Scholar]
  18. Reece D. E., Connors J. M., Spinelli J. J., Barnett M. J., Fairey R. N., Klingemann H. G., Nantel S. H., O'Reilly S., Shepherd J. D., Sutherland H. J. Intensive therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood. 1994 Mar 1;83(5):1193–1199. [PubMed] [Google Scholar]
  19. Tourani J. M., Levy R., Colonna P., Desablens B., Leprise P. Y., Guilhot F., Brahimi S., Belhani M., Ifrah N., Sensebe L. High-dose salvage chemotherapy without bone marrow transplantation for adult patients with refractory Hodgkin's disease. J Clin Oncol. 1992 Jul;10(7):1086–1094. doi: 10.1200/JCO.1992.10.7.1086. [DOI] [PubMed] [Google Scholar]
  20. Yahalom J., Gulati S. C., Toia M., Maslak P., McCarron E. G., O'Brien J. P., Portlock C. S., Straus D. J., Phillips J., Fuks Z. Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease. J Clin Oncol. 1993 Jun;11(6):1062–1070. doi: 10.1200/JCO.1993.11.6.1062. [DOI] [PubMed] [Google Scholar]
  21. Zulian G. B., Selby P., Milan S., Nandi A., Gore M., Forgeson G., Perren T. J., McElwain T. J. High dose melphalan, BCNU and etoposide with autologous bone marrow transplantation for Hodgkin's disease. Br J Cancer. 1989 Apr;59(4):631–635. doi: 10.1038/bjc.1989.128. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES